TEM · Tempus AI Inc.
The AI's read
Merck and Moderna posted a positive Phase 3 readout for a personalized mRNA cancer vaccine that relies on Personalis' tumor-profiling. Tempus agreed to acquire Personalis last month, so the trial result directly ties to Tempus' upcoming sequencing asset. The market is already reacting — TEM is up ~4.4% today and the source notes the stock is about 33% above its 20-day SMA with RSI in overbought territory. That extension raises the odds of a near-term pause or pullback even if the strategic case stays intact. We lean bullish because the trial win creates concrete commercial optionality for Tempus through Personalis' tech. Conviction is tempered by stretched momentum and a downtrend market, so upside looks event-driven unless follow-through arrives.